G1 Therapeutics, a clinical-stage biotech developing novel therapeutics for cancer, filed on Thursday with the SEC to raise up to $115 million in an initial public offering.
The Research Triangle Park, NC-based company was founded in 2008 and it plans to list on the Nasdaq under the symbol GTHX. G1 Therapeutics filed confidentially on February 5, 2017. J.P. Morgan, Cowen & Company, Needham & Co. and Wedbush Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Cancer biotech G1 Therapeutics files for a $115 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
